A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Study Summary

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

Conditions

Chronic Graft-Versus-Host Disease (cGVHD)

Interventions / Drugs

Vimseltinib

View on ClinicalTrials.gov ↗

Sponsor

DCPH

Deciphera Pharmaceuticals

Oncology

D40/100

Study Details

Enrollment48 participants

Primary Completion—

Lead SponsorDeciphera Pharmaceuticals, LLC

Data Retrieved2026-04-11 04:11:28.433224+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.